Broad-Spectrum Antibiotics Ineffective as Initial Pneumonia Treatment
|
By HospiMedica International staff writers Posted on 09 Mar 2020 |
A new study shows that hospitalized pneumonia patients prescribed antibiotics that target methicillin-resistant Staphylococcus aureus (MRSA) fare no better than standard medical care.
Researchers at the Veterans Affairs Salt Lake City Health Care System (UT, USA) and the University of Utah (UU; Salt Lake City, USA) conducted a retrospective cohort study involving 88,605 hospitalized patients (median age 70 years, predominantly men) who received either anti-MRSA or standard therapy for community-onset pneumonia. The main outcomes were 30-day all-cause mortality, after adjustment for patient comorbidities, vital signs, and laboratory results. Secondary outcomes included kidney injury and secondary infections with Clostridioides difficile, vancomycin-resistant Enterococcus species, or gram-negative bacilli.
The results revealed no discernable benefit of anti-MRSA treatment in addition to standard treatment. In fact, anti-MRSA treatment was associated with a 40 % higher risk of dying within 30 days of discharge, perhaps due to potentially severe side effects of vancomycin, including increased incidence of kidney failure and secondary infections. The researchers also observed that as doctors became more aware of MRSA infection in the lungs, they tended to use anti-MRSA drugs as initial treatment, despite the fact that MRSA only accounts for about 2% of pneumonia cases. The study was published on February 17, 2020, in JAMA Internal Medicine.
“In the absence of better tests to identify MRSA as a potential pathogen causing the disease, using anti-MRSA therapies does not seem to offer any advantage over standard treatment therapy,” said lead author Barbara Ellen Jones, MD, MSc, of UU. “Under these circumstances, it may be safer for patients if physicians to stick to standard antibiotic treatments for a couple of days to see how patients are doing, rather than leaping into anti-MRSA therapy right off the bat.”
Pneumonia is the eighth leading cause of death in the United States, accounting for more than one million hospitalizations and about 50,000 deaths each year. It can be caused by viruses, fungi, and bacteria, including MRSA.
Related Links:
Veterans Affairs Salt Lake City Health Care System
University of Utah
Researchers at the Veterans Affairs Salt Lake City Health Care System (UT, USA) and the University of Utah (UU; Salt Lake City, USA) conducted a retrospective cohort study involving 88,605 hospitalized patients (median age 70 years, predominantly men) who received either anti-MRSA or standard therapy for community-onset pneumonia. The main outcomes were 30-day all-cause mortality, after adjustment for patient comorbidities, vital signs, and laboratory results. Secondary outcomes included kidney injury and secondary infections with Clostridioides difficile, vancomycin-resistant Enterococcus species, or gram-negative bacilli.
The results revealed no discernable benefit of anti-MRSA treatment in addition to standard treatment. In fact, anti-MRSA treatment was associated with a 40 % higher risk of dying within 30 days of discharge, perhaps due to potentially severe side effects of vancomycin, including increased incidence of kidney failure and secondary infections. The researchers also observed that as doctors became more aware of MRSA infection in the lungs, they tended to use anti-MRSA drugs as initial treatment, despite the fact that MRSA only accounts for about 2% of pneumonia cases. The study was published on February 17, 2020, in JAMA Internal Medicine.
“In the absence of better tests to identify MRSA as a potential pathogen causing the disease, using anti-MRSA therapies does not seem to offer any advantage over standard treatment therapy,” said lead author Barbara Ellen Jones, MD, MSc, of UU. “Under these circumstances, it may be safer for patients if physicians to stick to standard antibiotic treatments for a couple of days to see how patients are doing, rather than leaping into anti-MRSA therapy right off the bat.”
Pneumonia is the eighth leading cause of death in the United States, accounting for more than one million hospitalizations and about 50,000 deaths each year. It can be caused by viruses, fungi, and bacteria, including MRSA.
Related Links:
Veterans Affairs Salt Lake City Health Care System
University of Utah
Latest Critical Care News
- 'Universal' Kidney to Match Any Blood Type
- AI Heart Attack Risk Assessment Tool Outperforms Existing Methods
- Smartphone Imaging System Enables Early Oral Cancer Detection
- Swallowable Pill-Sized Bioprinter Treats GI Tract Injuries

- Personalized Brain “Pacemakers” Could Help Patients with Hard-To-Treat Epilepsy
- Microscopic DNA Flower Robots to Enable Precision Medicine Delivery
- Origami Robots to Deliver Medicine Less Invasively and More Effectively
- Improved Cough-Detection Technology Aids Health Monitoring
- AI Identifies Children in ER Likely to Develop Sepsis Within 48 Hours
- New Radiofrequency Therapy Slows Glioblastoma Growth
- Battery-Free Wireless Multi-Sensing Platform Revolutionizes Pressure Injury Detection
- Multimodal AI to Revolutionize Cardiovascular Disease Diagnosis and Treatment
- AI System Reveals Hidden Diagnostic Patterns in Electronic Health Records
- Highly Sensitive On-Skin Sensing Monitor Detects Vitamin B6 and Glucose in Sweat
- Artificial Intelligence Revolutionizing Pediatric Anesthesia Management
- New Device Detects Tuberculosis DNA Directly in Exhaled Air
Channels
Surgical Techniques
view channel
Minimally Invasive Endoscopic Surgery Improves Severe Stroke Outcomes
Intracerebral hemorrhage, a type of stroke caused by bleeding deep within the brain, remains one of the most challenging neurological emergencies to treat. Accounting for about 15% of all strokes, it carries... Read more
Novel Glue Prevents Complications After Breast Cancer Surgery
Seroma and prolonged lymphorrhea are among the most common complications following axillary lymphadenectomy in breast cancer patients. These postoperative issues can delay recovery and postpone the start... Read morePatient Care
view channel
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
VR Training Tool Combats Contamination of Portable Medical Equipment
Healthcare-associated infections (HAIs) impact one in every 31 patients, cause nearly 100,000 deaths each year, and cost USD 28.4 billion in direct medical expenses. Notably, up to 75% of these infections... Read more
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read moreFirst-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read moreHealth IT
view channel
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read moreBusiness
view channel
Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies
Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
B. Braun Acquires Digital Microsurgery Company True Digital Surgery
The high-end microsurgery market in neurosurgery, spine, and ENT is undergoing a significant transformation. Traditional analog microscopes are giving way to digital exoscopes, which provide improved visualization,... Read more
CMEF 2025 to Promote Holistic and High-Quality Development of Medical and Health Industry
The 92nd China International Medical Equipment Fair (CMEF 2025) Autumn Exhibition is scheduled to be held from September 26 to 29 at the China Import and Export Fair Complex (Canton Fair Complex) in Guangzhou.... Read more







